Ibnsina Pharma (CAI:ISPH) Stock Price, Trades & News

Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.

Financial Strength

3/10

Name	Current	Vs Industry
Cash-To-Debt	0.18
Equity-to-Asset	0.07
Debt-to-Equity	2.55
Debt-to-EBITDA	1.86
Interest Coverage	1.46
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.67	Distress Grey Safe
Beneish M-Score	-2.45	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	51
	3-Year EBITDA Growth Rate	68
	3-Year EPS without NRI Growth Rate	96.4
	3-Year FCF Growth Rate	-22.2
	3-Year Book Growth Rate	30.3
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	55.5
	Future 3-5Y Total Revenue Growth Rate Estimate	13.35

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	72.36
	9-Day RSI	56.82
	14-Day RSI	52.27
	3-1 Month Momentum %	13.72
	6-1 Month Momentum %	10.53
	12-1 Month Momentum %	23.17

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.03
	Quick Ratio	0.73
	Cash Ratio	0.04
	Days Inventory	42.76
	Days Sales Outstanding	88.95
	Days Payable	118.77

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.12
	Dividend Payout Ratio	0.19
	3-Year Dividend Growth Rate	17
	Forward Dividend Yield %	1.12
	5-Year Yield-on-Cost %	1.13
	Shareholder Yield %	-14.13

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	8.32
	Operating Margin %	4.39
	Net Margin %	1.28
	EBITDA Margin %	4.93
	FCF Margin %	1.11
	OCF Margin %	2.4
	ROE %	40.33
	ROA %	2.9
	ROIC %	29.47
	3-Year ROIIC %	66.12
	ROC (Joel Greenblatt) %	50.55
	ROCE %	92.4
	Years of Profitability over Past 10-Year	10

GF Value Rank

9/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	14.14
	Forward PE Ratio	7.61
	PE Ratio without NRI	14.14
	Shiller PE Ratio	38.41
	Price-to-Owner-Earnings	8.79
	PEG Ratio	0.29
	PS Ratio	0.14
	PB Ratio	4.1
	Price-to-Tangible-Book	4.46
	Price-to-Free-Cash-Flow	13.34
	Price-to-Operating-Cash-Flow	6.17
	EV-to-EBIT	5.61
	EV-to-Forward-EBIT	8.13
	EV-to-EBITDA	5.09
	EV-to-Forward-EBITDA	6.32
	EV-to-Revenue	0.25
	EV-to-Forward-Revenue	0.2
	EV-to-FCF	22.66
	Price-to-GF-Value	1.11
	Price-to-Peter-Lynch-Fair-Value	0.57
	Price-to-Graham-Number	1.67
	Earnings Yield (Greenblatt) %	17.83
	FCF Yield %	6.98
	Forward Rate of Return (Yacktman) %	16.13

Financials

Annual Quarterly TTM

CAI:ISPH's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Ibnsina Pharma Executives

Details

GF Value™: E£10.56

CAI:ISPH

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with ISPH. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil E£)	80,053.03
	EPS (TTM) (E£)	0.83
	Beta	-
	3-Year Sharpe Ratio	1.15
	3-Year Sortino Ratio	2.23
	Volatility %	28.31
	14-Day RSI	52.27
	14-Day ATR (E£)	0.264311
	20-Day SMA (E£)	11.587
	12-1 Month Momentum %	23.17
	52-Week Range (E£)	9.63 - 13.72
	Shares Outstanding (Mil)	1,008

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Ibnsina Pharma Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Ibnsina Pharma Stock Events

Financials Calendars

Event	Date	Price (E£)
EGP 0.130000 Cash Dividend	2026-04-27	11.07 (+0.09%)
EGP 0.160000 Cash Dividend	2025-10-13	11.77 (+0.86%)
1.16733:1 Stock Split	2022-06-01	1.62 (-3.57%)
1.17073:1 Stock Split	2020-10-01	5.33 (+3.85%)
1.13573:1 Stock Split	2019-07-15	7.15 (-0.72%)

Show

Entries

Ibnsina Pharma Frequently Asked Questions

What is Ibnsina Pharma(CAI:ISPH)'s stock price today?

The current price of CAI:ISPH is E£11.73. The 52 week high of CAI:ISPH is E£13.72 and 52 week low is E£9.63.

When is next earnings date of Ibnsina Pharma(CAI:ISPH)?

The next earnings date of Ibnsina Pharma(CAI:ISPH) is .

Does Ibnsina Pharma(CAI:ISPH) pay dividends? If so, how much?

The Dividend Yield % of Ibnsina Pharma(CAI:ISPH) is 1.12% (As of Today), Highest Dividend Payout Ratio of Ibnsina Pharma(CAI:ISPH) was 1.09. The lowest was 0.19. And the median was 0.27. The Forward Dividend Yield % of Ibnsina Pharma(CAI:ISPH) is 1.12%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
No Press Release

Articles on Ibnsina Pharma

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.